Genetics of the myeloproliferative neoplasms

Current Opinion in Hematology

Volumn 18, Issue 2, 2011, Pages 117-123

  Abdel Wahab, Omar ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ASXL1; EZH2; IDH1 2; JAK2; TET2

Indexed keywords

ADAPTOR PROTEIN; IKAROS TRANSCRIPTION FACTOR; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; JANUS KINASE 2; ONCOPROTEIN; POLYCOMB GROUP PROTEIN; PROTEIN ASXL1; PROTEIN LNK; PROTEIN MPL; PROTEIN TET2; STAT PROTEIN; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; DNA METHYLATION; ENZYME MECHANISM; EXON; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PATHOGENESIS; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

DNA-BINDING PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 79952042287     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328343998e     Document Type: Article

References (61)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6:372-375.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-1061. (Pubitemid 40386783)
3. James C, UgoV, LeCouedic JP, etal.A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144-1148. (Pubitemid 40663494)
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-1790. (Pubitemid 40570926)
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387-397. (Pubitemid 40544655)
6. Abdel-Wahab O, Kilpivaara O, Patel J, et al. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX1 2) is not a somatic alteration. Leukemia 2010; 24:1656-1657.
7. Abdel-Wahab O, Levine, RL. Genetics of the myeloproliferative neoplasms. In: Verstovsek S, Tefferi A, editors. Myeloproliferative neoplasms. Vol. 1. 1st ed. New York: Springer; 2010. pp. 39-69.
8. Pikman Y, Lee BH, MercherT, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3:e270.
9. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459-468. (Pubitemid 46193073)
10. Lasho TL, Pardanani A, Tefferi A. LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med 2010; 363:1189-1190.
11. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor • protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116:988-992.
12. Pardanani A, Lasho T, Finke C, et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010; 24:1713-1718.
13. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7:673-683. (Pubitemid 47327415)
14. Takaki S, Morita H, Tezuka Y, Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med 2002; 195:151-160. (Pubitemid 34461259)
15. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 2004; 200:569-580. (Pubitemid 39258306)
16. Velazquez L, Cheng AM, Fleming HE, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 2002; 195:1599-1611. (Pubitemid 34666073)
17. Baran-MarszakF, Magdoud H, Desterke C, et al. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood 2010; 116:5961-571.
18. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003; 102:3793-3796. (Pubitemid 37409402)
19. Landgren O, Goldin LR, Kristinsson SY, etal. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 2008; 112:2199-2204.
20. Rumi E, Passamonti F, Della Porta MG, etal. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007; 25:5630-5635.
21. Rumi E, Passamonti F, Pietra D, etal. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006; 107:2206-2211. (Pubitemid 44665655)
22. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 2009; 41:446-449.
23. Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41:455-459.
24. Olcaydu D, Harutyunyan A, Jager R, etal. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 2009; 41:450-454.
25. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid •• cancers. N Engl J Med 2009; 360:2289-2301.
26. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41:838-842.
27. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114:144-147.
28. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23:900-904.
29. Tefferi A, Lim KH, Abdel-Wahab O, etal. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/ MPN and AML. Leukemia 2009; 23:1343-1345.
30. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009; 23:905-911.
31. Perez B, Kosmider O, Cassinat B, et al. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br J Haematol 2010; 151:460-468.
32. Szpurka H, Jankowska AM, Makishima H, et al. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leuk Res 2010; 34:969-973.
33. Lorsbach RB, Moore J, Mathew S, et al. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003; 17:637-641. (Pubitemid 36395661)
34. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to •• 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324:930-935.
35. Ito S, D'Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466:1129-1133.
36. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcy- • tosine in myeloid cancers with mutant TET2. Nature 2010; 468:839-843.
37. Figueroa M, Abdel-Wahab O, Lu C, etal. Leukemic IDH1 and IDH2 mutations • result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553-567.
38. Abdel-Wahab O, Manshouri T, Patel J, etal. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70:447-452.
39. Beer PA, Delhommeau F, Lecouedic JP, et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010; 115:2891-2900.
40. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1812.
41. Yan H, Parsons DW, Jin G, etal. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-773.
42. Mardis ER, Ding L, Dooling DJ, etal. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361:1058-1066.
43. Zhao R, Follows GA, Beer PA, et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med 2008; 359:2778-2789.
44. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations •• produce 2-hydroxyglutarate. Nature 2009; 462:739-744.
45. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207:339-344.
46. Ward PS, Patel J, Wise DR, etal. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17:225-234.
47. Tefferi A, LashoTL, Abdel-Wahab O, etal. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24:1302-1309.
48. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia (AML): prevalence and prognostic value. Blood 2010; 116:2122-2126.
49. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28:3636-3643.
50. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone • methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722-776.
51. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42:665-667.
52. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42:181-185.
53. Abdel-Wahab O, Manshouri T, Patel J, etal. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70:447-452.
54. Boultwood J, Perry J, Pellagatti A, et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010; 24:1062-1065.
55. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23:2183-2186.
56. Gelsi-BoyerV, Trouplin V, Adelaide J, etal. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145:788-800.
57. Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010; 151:365-375.
58. Boultwood J, Perry J, Zaman R, etal. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia 2010; 24:1139-1145.
59. Fisher CL, Lee I, Bloyer S, et al. Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice. Dev Biol 2010; 337:9-15.
60. Cho YS, Kim EJ, Park UH, et al. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J Biol Chem 2006; 281:17588-17598.
61. Fisher CL, Pineault N, Brookes C, etal. Loss-of-function additional sexcombs-like1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010; 115:38-46.